Causes: Diagnosed with mitral stenosis don’t recall ever having the illness. During rheumatic fever, the valve becomes Mitral stenosis most commonly develops many years after a person has had rheumatic fever, although many patients inflamed. Over time, the leaflets of the inflamed valve stick together and become scarred, rigid and thickened, limiting its ability to open completely.
Symptoms: Many of the symptoms of mitral stenosis, such as shortness of breath and fatigue, result from a back-up of blood in the lungs. Other symptoms of mitral stenosis may include quick weight gain; weakness; dizziness; swelling in the ankles, feet and/or abdomen (edema); and/or heart palpitations (irregular heartbeat).
Treatment: A balloon valvotomy is the preferred treatment for mitral valve stenosis. It is a procedure that widens the mitral valve so that blood flows more easily through the heart. A balloon valvotomy is a minimally invasive procedure. A doctor uses a thin flexible tube (catheter) that is inserted through an artery in the groin or arm and threaded into the heart. When the tube reaches the narrowed mitral valve, a balloon device located on the tip of the catheter is quickly inflated. The narrowed or fused mitral valve leaflets are separated and stretched open as the balloon presses against them. This process increases the size of the mitral valve opening and allows more blood to flow from the left atrium into the left ventricle.
Statistics: In the current study the evaluation of the data of a total number of 282 patientswith HF in the district provied us to gain these following results: Of the patients with HFthe prevalence of HT 40.8‰,AF 38.8‰,and DM 35.5‰ respectively. Moreover, of thepatients with HF, 34.4‰‰ were cigarette smokers.The mean values of EF35.5+8.3‰, HCT 36.2+4.7‰ and creatinin levels were 1.3+0.7 mg/dL. Receiver operating characteristic analysis revealed that an MBL cutoff value of 0.5 âªg/mL was a reliable predictor of low-producingMBL2 genotypes (sensitivity, 82%; specificity, 82%; negative predictive value, 98%). MBL deficiency was associated with increased likelihood of death among patients with severe bacterial infection (odds ratio, 2.11; 95% confidence interval, 1.30–3.43). In intensive care unit–based studies, there was a trend toward increased risk of death among MBL-deficient patients (odds ratio, 1.58; 95% confidence interval, 0.90–2.77) after adjustment for Acute Physiology and Chronic Health Enquiry II score. The risk of death was increased among MBL-deficient patients with Streptococcus pneumoniae infection (odds ratio, 5.62; 95% confidence interval, 1.27–24.92) after adjustment for bacteremia, comorbidities, and age.